|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors.
|
30065701 |
2018 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
p27/Kip1 mutation found in breast cancer.
|
8625318 |
1996 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that breast cancer may be associated with CDKN1B gene rs34330 polymorphism, but not rs2066827 polymorphism.
|
24078094 |
2013 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The 95% confidence intervals for per allele risk estimates excluded a twofold risk, indicating that common CDKN1B polymorphisms do not markedly modify breast cancer risk among BRCA1 or BRCA2 carriers.
|
18543099 |
2009 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on this meta-analysis, we conclude that the cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism might not be a risk factor for breast cancer development.
|
24523023 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the determination of the CDKN1B genotype might be a powerful tool for the prognosis of patients with early breast cancer.
|
15627896 |
2005 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although the exact biological mechanism remains to be explored, our findings suggest possible involvement of CDKN1A and CDKN1B variants in the etiology of breast cancer.
|
16804901 |
2006 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This approach found evidence for breast cancer-associated SNPs in four of the cell cycle genes: the cyclin CCNE1 rs997669 had an odds ratio (OR) (GG/AA) of 1.18 [95% confidence interval (95% CI) 1.04-1.34] P = 0.003 and the cyclin-dependent kinase inhibitors-CDKN1A rs3176336: OR (TT/AA) = 1.25 (95% CI 1.11-1.42) P = 0.0026; CDKN1B rs34330: OR (TT/CC) = 1.22 (95% CI 1.02-1.47) P = 0.013 and the region of CDKN2A/2B rs3731239: OR (CC/TT) = 0.90 (95% CI 0.79-1.03) P = 0.013 and rs3218005 OR (GG/AA) = 1.55 (95% CI 1.02-2.37) P = 0.013 (P-values unadjusted for multiple testing).
|
18174243 |
2008 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study we analyzed the effect of simultaneous FOXO3 silencing and p27Kip1 activation on breast cancer cell survival and the potential targets of these changes in cancer molecular pathways.
|
31294654 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a parsimonious multivariable proportional hazards model, protein levels of cyclin E, p27(Kip1), p53, and the presence of glomeruloid microvascular proliferation all independently predicted outcome after breast cancer.
|
14871808 |
2004 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated levels of the cell cycle protein cyclin E, and low levels of its inhibitor, p27(Kip1), have been associated with a poor prognosis following breast cancer.
|
15802279 |
2005 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cyclin-dependent kinase inhibitor p27 (Kip1) is an important cell cycle regulatory gene in breast cancer, and decreased p27 expression is associated with poor prognosis.
|
15082918 |
2004 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Through pharmacologic approaches, we demonstrated that SRC and PKC negatively regulated expression of the cell-cycle inhibitor protein p27KIP1, and are necessary for CCL2-induced breast cancer cell proliferation.
|
30446625 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the data reported here demonstrate that miR-24-3p is an important regulator in breast cancer, and imply that the miR-24-3p/p27Kip1 axis has potential as a therapeutic target for breast cancer.
|
26044523 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.
|
8557269 |
1996 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture.
|
30559257 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest that agents that up-regulate p27(Kip1) or inhibit growth factor signaling via the extracellular signal-regulated kinases should be tested as therapeutic strategies in tamoxifen-resistant breast cancer.
|
12907598 |
2003 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further propose p27KIP1 expression level may be also a candidate predictive biomarker of rapalogs for breast cancer therapy, which requires additional clinical validation.
|
25744729 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggested that Emi1's anti-apoptotic and proliferative abilities appear to be triggered at least in part by the modulation of Skp2, combined Emi1 and Skp2 expressions, may be prognostic for patients with invasive breast carcinomas, which also associated with p-Akt and enabled p27(kip1) degradation.
|
24277465 |
2013 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Over-expression of the ubiquitin ligase Skp2 results in loss of the cell cycle inhibitor p27Kip1 and is associated with poor prognosis in early breast cancer.
|
18644126 |
2008 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cyclin-dependent kinase inhibitor p27 plays a central role in cell cycle progression and is deregulated in breast carcinomas.
|
12015771 |
2002 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.
|
20683061 |
2010 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To address this question, here, we transfected the MCF7 breast cancer cell line and the MCF10F nontumorigenic mammary epithelial cell line with a vector containing the p27Kip1 cDNA to obtain derivatives that express increased levels of p27Kip1.
|
9699679 |
1998 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, the recombinant adenovirus expressing mutant p27(kip1) could be useful in gene therapy against breast cancer.
|
18030569 |
2007 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of the transfected p21 (Waf1) -p27 (Kip1) gene on centrosome duplication, cell proliferation, and apoptosis of MCF-7, a breast cancer cell line.
|
23338153 |
2014 |